NEW YORK, March 7, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Analysts Review released its analysts' notes regarding
MDU Resources Group Inc. (NYSE: MDU), UGI Corp. (NYSE: UGI),
Vectren Corporation (NYSE: VVC), ALLETE, Inc. (NYSE: ALE), and
Avista Corp. (NYSE: AVA). Private wealth members receive these
notes ahead of publication. To reserve complementary membership,
limited openings are available at:
http://www.AnalystsReview.com/register
MDU Resources Group Inc. Analyst
Notes
On March 4, 2014, MDU Resources
Group Inc.'s (MDU Resources) stock increased 1.04%, ending the day
at $33.90. Over the previous three
trading sessions, shares of MDU Resources declined 0.59%, compared
to the Dow Jones Industrial Average which advanced 0.76% during the
same period. The full analyst notes on MDU Resources Group Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03052014/MDU/report.pdf
UGI Corp. Analyst Notes
On March 4, 2014, UGI Corp.'s
(UGI) stock increased 0.84%, ending the day at $44.67. Over the previous three trading sessions,
shares of UGI increased 0.70%, compared to the Dow Jones Industrial
Average which gained 0.76% during the same period. The full analyst
notes on UGI Corp. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/UGI/report.pdf
Vectren Corporation Analyst Notes
On February 19, 2014, Vectren
Corporation (Vectren) reported its financial results for Q4 2013
and full year 2013. The Company reported annual consolidated net
income of $136.6 million, or
$1.66 per diluted share, versus net
income of $159.0 million, or
$1.94 per diluted share in full year
2012. According to the Company, Utility Group earnings were
$141.8 million in full year 2013,
versus $138.0 million in full year
2012; while Nonutility Group earnings were $33.0 million in full year 2013, (not including
the results of ProLiance), versus earnings of $21.7 million in full year 2012. Q4 2013
consolidated net income was $49.8
million, or $0.60 per diluted
share, versus net income of $42.8
million, or $0.52 per diluted
share, in Q4 2012. Full year 2013 operating revenues were reported
to be $2.5 billion, up 11.6% YoY;
while quarterly revenues increased 5.6% YoY to $680.0 million. The Company stated that for full
year 2014, it anticipates consolidated earnings of $2.15 to $2.35 per share. The full analyst notes
on Vectren Corporation are available to download free of charge
at:
http://www.AnalystsReview.com/03052014/VVC/report.pdf
ALLETE, Inc. Analyst Notes
On February 26, 2014, ALLETE, Inc.
(ALLETE) announced the pricing of an underwritten public offering
of 2.8 million shares of its common stock at $49.75 per share in connection with the forward
sale agreement. The Company informed that the size of the offering
was increased from the previously announced 2.5 million shares.
ALLETE stated that together with this offering, the underwriters
have been granted an option to purchase an additional 420,000
shares of the Company's common stock solely to cover
over-allotments, if any. The Company added that it plans to use net
proceeds from settlement of the forward sale agreement or upon
issuance and sale to the underwriters of shares for corporate
purposes, including capital investments. ALLETE informed that J.P.
Morgan and Baird are acting as joint book-running managers for the
offering, and RBC Capital Markets and Wells Fargo Securities are
acting as co-managers for the offering. The Company further stated
that it entered into a forward sale agreement in connection with
the offering with an affiliate of J.P. Morgan (the Counterparty)
under which the Company agrees to sell to the Counterparty the same
number of shares of the Company's common stock sold by an affiliate
of the Counterparty to the underwriters for sale in the
underwritten public offering. The full analyst notes on ALLETE,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/ALE/report.pdf
Avista Corp. Analyst Notes
On February 26, 2014, Avista Corp.
(Avista) reported its financial results for Q4 2013 and full year
2013.
The Company declared net income attributable to Avista
shareholders of $111.1 million, or
$1.85 per diluted share, for full
year 2013, versus $78.2 million, or
$1.32 per diluted share, for full
year 2012. For Q4 2013, net income attributable to Avista
shareholders was $31.7 million, or
$0.53 per diluted share, versus
$15.9 million, or $0.26 per diluted share, for Q4 2012. Full-year
2013 operating revenues increased 4.6% YoY to $1.6 billion, while quarterly operating revenues
grew to $447.7 million, up 9.0% YoY.
Avista Chairman, President and CEO Scott
Morris, commented, "We had a very good year in 2013, with
utility earnings above our expectations, and significant
improvement at Ecova as compared to 2012." He added, "Lastly, we
are confirming our 2014 earnings guidance with a consolidated range
of $1.77 to $1.97 per diluted share.
This excludes any impact from the planned acquisition of AERC." The
full analyst notes on Avista Corp. are available to download free
of charge at:
http://www.AnalystsReview.com/03052014/AVA/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review